스코폴아민을 이용한 치매 동물 모델 연구
A Study on the Animal Model for Dementia Induced by Scopolamine
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
This study aimed to determine dose of scopolamine to induce cognitive and memory dysfunction in rat. Six-week-old male rats (n=20) were randomly divided four groups. Scopolamine bromide (0, 0.5, 1.0 and 2.0 mg/kg) was intraperitoneally injected for 7 days. From 4-7 days after injection, the rats were performed memory test by water maze and passive avoidance test. On the 8th day, the rats were sacrificed, then acetylcholinesterase (AChE) activity, cholinergic proteins and inflammatory mediators were analyzed from their brain tissue. In the memory test and AChE activity, the group of scopolamine treatment (0.5 mg/kg) showed no significant difference compared to the control group (0 mg/kg). But, they showed significant differences compared to the control group in expression of choline transporter, choline acetyltransferase, and vesicular acetylcholine transporter protein and nuclear factor kappa B, tumor necrosis factor-α, interLeukin-6, inducible nitric oxide synthase, and cyclooxygenase2 mRNA. Also, the groups of scopolamine treatment (1.0 and 2.0 mg/kg) showed significant differences compared to the control group in memory test, AChE activity, expression of cholinergic proteins and inflammatory mediators mRNA. Therefore, it was suggested that 1.0 mg/kg of scopolamine is adequate dose to induce cognitive and memory dysfunction in rats.
Abstract
This study aimed to determine dose of scopolamine to induce cognitive and memory dysfunction in rat. Six-week-old male rats (n=20) were randomly divided four groups. Scopolamine bromide (0, 0.5, 1.0 and 2.0 mg/kg) was intraperitoneally injected for 7 days. From 4-7 days after injection, the rats were performed memory test by water maze and passive avoidance test. On the 8th day, the rats were sacrificed, then acetylcholinesterase (AChE) activity, cholinergic proteins and inflammatory mediators were analyzed from their brain tissue. In the memory test and AChE activity, the group of scopolamine treatment (0.5 mg/kg) showed no significant difference compared to the control group (0 mg/kg). But, they showed significant differences compared to the control group in expression of choline transporter, choline acetyltransferase, and vesicular acetylcholine transporter protein and nuclear factor kappa B, tumor necrosis factor-α, interLeukin-6, inducible nitric oxide synthase, and cyclooxygenase2 mRNA. Also, the groups of scopolamine treatment (1.0 and 2.0 mg/kg) showed significant differences compared to the control group in memory test, AChE activity, expression of cholinergic proteins and inflammatory mediators mRNA. Therefore, it was suggested that 1.0 mg/kg of scopolamine is adequate dose to induce cognitive and memory dysfunction in rats.
참고문헌 (43)
- Alasmari, F., "Neuroinflammatory Cytokines Induce Amyloid Beta Neurotoxicity through Modulating Amyloid Precursor Protein Levels", Metabolism, 2018, pp.2018, 3087475~
- Arvanitakis, Z., "Diagnosis and Management of Dementia : Review", JAMA, 322, pp.1589~1599 (2019)[DOI]
- Ashrafian, H., "Review on Alzheimer's disease : Inhibition of amyloid beta and tau tangle formation", International Journal of Biological Macromolecules, 167, pp.382~394 (2021)[DOI]
- Bartus, R. T., "The cholinergic hypothesis of geriatric memory dysfunction", Science, 217, pp.408~414 (1982)[DOI]
- Bejar, C., "Effect of rivastigmine on scopolamine-induced memory impairment in rats", European Journal of Pharmacology, 383, pp.231~240 (1999)[DOI]
- Buxbaum, J. D., "Regulation of APP processing by intra-and intercellular signals", Annals of the New York Academy of Sciences, 777, pp.327~331 (1996)[DOI]
- Chen, W. N., "Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer's Disease", CNS & Neurological Disorders Drug Targets, 19, pp.85~93 (2020)[DOI]
- Jeffrey Cummings, "Alzheimer's disease drug development pipeline: 2021", Alzheimer's & Dementia: Translational Research & Clinical Interventions, 7(1) (2021), Wiley[DOI]
- Dheen, S. T., "Microglial activation and its implications in the brain diseases", Current Medicinal Chemistry, 14, pp.1189~1197 (2007)[DOI]
- Drummond, E., "Alzheimer's disease : experimental models and reality", Acta Neuropathologica, 133, pp.155~175 (2017)[DOI]
- Esquerda-Canals, G., "Mouse Models of Alzheimer's Disease", Journal of Alzheimers Disease, 57, pp.1171~1183 (2017)[DOI]
- Ferreira-Vieira, T. H., "Alzheimer's disease : Targeting the Cholinergic System", Current Neuropharmacology, 14, pp.101~115 (2016)[DOI]
- Steffen Gais, "Low acetylcholine during slow-wave sleep is critical for declarative memory consolidation", Proceedings of the National Academy of Sciences, 101(7), pp.2140~2144 (2004), Proceedings of the National Academy of Sciences[DOI]
- Gao, Y., "Tau in Alzheimer's Disease : Mechanisms and Therapeutic Strategies", Current Alzheimer Research, 15, pp.283~300 (2018)[DOI]
- Mahanandeeshwar Gattu, "Reversal of Scopolamine-Induced Deficits in Navigational Memory Performance by the Seed Oil of Celastrus paniculatus", Pharmacology Biochemistry and Behavior, 57(4), pp.793~799 (1997), Elsevier BV[DOI]
- Gilles, C., "Pharmacological models in Alzheimer's disease research", Dialogues in Clinical Neuroscience, 2, pp.247~255 (2000)[DOI]
- Yuan-Ri Guo, "Synergistic Neuroprotective Effects of Mature Silkworm and Angelica gigas Against Scopolamine-Induced Mild Cognitive Impairment in Mice and H2O2-Induced Cell Death in HT22 Mouse Hippocampal Neuronal Cells", Journal of Medicinal Food, 24(5), pp.505~516 (2021), 한국식품영양과학회[DOI]
- Hermans, R. H., "Behavioral sequelae in young rats of acute intermittent antenatal hypoxia", Neurotoxicology and Teratology, 14, pp.119~129 (1992)[DOI]
- Huang, L. K., "Clinical trials of new drugs for Alzheimer disease", Journal of Biomedical Science, 27, pp.18~ (2020)[DOI]
- Jafarian, S., "Effect of zerumbone on scopolamine-induced memory impairment and anxiety-like behaviours in rats", Alzheimers and Dementia(New York), 5, pp.637~643 (2019)[DOI]
- Kinney, J. W., "Inflammation as a central mechanism in Alzheimer's disease", Alzheimers and Dementia(New York), 4, pp.575~590 (2018)[DOI]
- Kitazawa, M., "Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease", Journal of Neuroscience, 25, pp.8843~8853 (2005)[DOI]
- Klinkenberg, I., "The validity of scopolamine as a pharmacological model for cognitive impairment : a review of animal behavioral studies", Neuroscience and Biobehavioral Reviews, 34, pp.1307~1350 (2010)[DOI]
- Marucci, G., "Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease", Neuropharmacology, 190, pp.108352~ (2021)[DOI]
- Sandeep More, "Toxin-Induced Experimental Models of Learning and Memory Impairment", International Journal of Molecular Sciences, 17(9), pp.1447~ (2016), MDPI AG[DOI]
- Morris, R., "Developments of a water-maze procedure for studying spatial learning in the rat", J Neurosci Methods, 11, pp.47~60 (1984)[DOI]
- Tsuyoshi Nakai, "Alzheimer’s Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment", International Journal of Molecular Sciences, 22(11), pp.5549~ (2021), MDPI AG[DOI]
- So-Young Oh, "Central administration of afzelin extracted from Ribes fasciculatum improves cognitive and memory function in a mouse model of dementia", Scientific Reports, 11(1) (2021), Springer Science and Business Media LLC[DOI]
- Dongsun Park, "Human Neural Stem Cells Encoding ChAT Gene Restore Cognitive Function via Acetylcholine Synthesis, Aβ Elimination, and Neuroregeneration in APPswe", PS1dE9 Mice, 2020, pp.21(11), 3958~[DOI]
- Dongsun Park, "Human neural stem cells over-expressing choline acetyltransferase restore cognition in rat model of cognitive dysfunction", Experimental Neurology, 234(2), pp.521~526 (2012), Elsevier BV[DOI]
- Dongsun Park, "Improvement of cognitive function and physical activity of aging mice by human neural stem cells over-expressing choline acetyltransferase", Neurobiology of Aging, 34(11), pp.2639~2646 (2013), Elsevier BV[DOI]
- Perry, E., "Acetylcholine and Alzheimer's disease", The British Journal of Psychiatry, 152, pp.737~740 (1988)[DOI]
- Pinheiro, L., "Therapeutic Strategies Targeting Amyloid-beta in Alzheimer's Disease", Current Alzheimer Research, 16, pp.418~452 (2019)[DOI]
- Rogers, J. L., "Cholinergic modulation of the hippocampus during encoding and retrieval", Neurobiology of Learning and Memory, 80, pp.332~342 (2003)[DOI]
- 신창열, "The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents", Biomolecules & Therapeutics, 26(3), pp.274~281 (2018), 한국응용약물학회
- Sommer, A., "The Trojan horse-neuroinflammatory impact of T cells in neurodegenerative diseases", Molecular Neurodegeneration, 12, pp.78~ (2017)[DOI]
- Statistics for the Elderly, "Statistics Korea", ~ (2020)
- Peng Sun, "Involvement of MAPK", NF-κB Signaling in the Activation of the Cholinergic Anti-Inflammatory Pathway in Experimental Colitis by Chronic Vagus Nerve Stimulation, 2013, pp.8(8), e69424~[DOI]
- Tang, K. S., "The cellular and molecular processes associated with scopolamine-induced memory deficit : A model of Alzheimer's biomarkers", Life Sciences, 233, pp.116695~ (2019)[DOI]
- Terry, R. D., "Dementia of the Alzheimer type", Annual Review of Neuroscience, 3, pp.77~95 (1980)[DOI]
- Jung-Min Yon, "The Ethanol Fraction of White Rose Petal Extract Abrogates Excitotoxicity-Induced Neuronal Damage In Vivo and In Vitro through Inhibition of Oxidative Stress and Proinflammation", Nutrients, 10(10), pp.1375~ (2018), MDPI AG[DOI]
- Zeiss, C. J., "Utility of spontaneous animal models of Alzheimer's disease in preclinical efficacy studies", Cell and Tissue Research, 380, pp.273~286 (2020)[DOI]
- Jiayi Zhao, "Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice", Scientific Reports, 9(1) (2019), Springer Science and Business Media LLC[DOI]